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A variety of modified fats that provide different functionalities are utilized in processed foods to 2 
optimize product characteristics and nutrient composition. Partial hydrogenation results in the 3 
formation of trans-fatty acids (TFAs) and was one of the most widely used modification 4 
processes of fats and oils. However, the negative effects of commercially produced TFAs on 5 
serum lipoproteins and risk for cardiovascular disease resulted in the Institute of Medicine and 6 
the 2010 US Dietary Guidelines for Americans both recommending that TFA intake be as low as 7 
possible. After its tentative 2013 determination that use of partially hydrogenated oils (PHOs) is 8 
not generally regarded as safe, the FDA released its final determination of the same in 2015. 9 
Many food technologists have turned to interesterified fat as a replacement. Interesterification 10 
rearranges fatty acids within and between a triglyceride molecule using either a chemical catalyst 11 
or an enzyme. Although there is clear utility of interesterified fats for retaining functional 12 
properties of food, the nutrition and health implications of long-term interesterified fat 13 
consumption are less well understood. The ILSI North America Technical Committee on Dietary 14 
Lipids sponsored a workshop to discuss the health effects of interesterified fats, identify research 15 
needs, and outline considerations for the design of future studies. Consensus was that although 16 
interesterified fat production is a feasible and economically viable solution for replacing dietary 17 
TFAs, outstanding questions must be answered regarding the effects of interesterification on 18 
modifying certain aspects of lipid and glucose metabolism, inflammatory responses, hemostatic 19 




A variety of modified fats that provide different functionalities are utilized in processed foods to 23 
optimize product characteristics and nutrient composition. Melting behavior, solid fat content, 24 
and fat crystal network are important factors in creating shortenings and margarines, whereas 25 
oxidative stability is important for frying oil. The desired property of lipids in foods may be 26 
achieved by blending, fractionation, hydrogenation, interesterification, or genetic modification. 27 
Until recently, partial hydrogenation was one of the most widely used modification processes of 28 
fats and oils. This process uses hydrogen to reduce the level of polyunsaturated fatty acids 29 
(PUFAs) while forming positional and geometric fatty acid (FA) isomers, including trans-fatty 30 
acids (TFAs), and saturated fatty acids (SFAs) to impart solid function to fats for shortenings 31 
and, in some cases, for stability to oils used for deep frying (1). Compared with unsaturated oils, 32 
this reduction in PUFAs to modify function also extends the shelf-life for packaged foods. With 33 
widespread use as an animal fat replacement in foods, partially hydrogenated oils (PHOs) 34 
became the prime source of TFAs in the diet. Industrially produced TFAs are unsaturated fatty 35 
acids (UFAs) with at least one carbon-carbon double bond in the trans configuration. In humans, 36 
plants, and most mammals, endogenously synthesized UFAs have double bonds that are 37 
overwhelmingly in the cis configuration. Only ruminants produce small amounts of TFAs in 38 
their rumen (2). Previous studies have described the negative effects of industrially produced 39 
TFAs on lipoproteins and cardiovascular disease risk (3). Beginning in 2006, the FDA required 40 
declaration of TFA content on nutrition labels (4). Both the Institute of Medicine and the 2010 41 
US Dietary Guidelines for Americans (5) recommended that TFA intake be kept as low as 42 
possible. After tentatively determining in 2013 that the use of PHOs is not generally regarded as 43 
safe (6), the FDA released its final determination of the same in 2015 (7). Food manufacturers 44 
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will have a 3-y compliance period to either reformulate their products without PHOs or petition 45 
the agency for permission for specific uses (7).  46 
Whereas nutritionists focus primarily on the health effects of specific FAs, food technologists 47 
tend to focus on product and ingredient functionality while also keeping health effects in mind.  48 
TG composition is an important indicator of the functionality of fats. In the search for alternative 49 
fats and oils to replace TFA, food technologists have turned to a process called interesterification 50 
(also known as the randomization of fats), which has been used in the edible oils industry for 51 
decades. Interesterification rearranges the FAs within and between a TG molecule using a 52 
chemical catalyst or enzyme. The chemical interesterification process is a random modification 53 
tool, whereas enzymatic interesterification can be either random or stereospecific. Depending on 54 
the starting fat and/or oils, more SFAs or UFAs can be exchanged into the sn-2 position, 55 
changing the original TG structure. This exchange is one way to modify the melting point of the 56 
fat without changing its FA composition while providing similar functional qualities as PHOs, 57 
without introducing TFAs.  58 
The creation of interesterified fats, also referred to as structured lipids, can also involve the 59 
replacement of naturally occurring long-chain FAs at the sn-1 and sn-3 positions with medium-60 
chain fatty acids (MCFAs), such as caprylic acid (8:0) or capric acid (10:0), to form medium-61 
chain triglycerides (MCTs), or with long-chain omega-3 FAs (DHA, EPA, and docosapentaenoic 62 
acid), long-chain omega-6 FAs (arachidonic acid), or long-chain SFAs (stearic acid), or other 63 
“atypical” FAs to produce novel fats. For example, MCTs are easily hydrolyzed, readily 64 
absorbed, and directly metabolized for energy, rather than accumulated as depot fat. This group 65 
of structured lipids imparts special nutritional or pharmaceutical properties and has historically 66 
been used for patients with abnormalities in fat digestion (8). MCTs have also been suggested to 67 
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facilitate weight loss (9). 68 
Although the utility of interesterified fats for retaining functional properties of food is clear, the 69 
health implications of long-term consumption are less well understood. Based on current 70 
understanding from the majority of published studies, it was previously assumed that the 71 
triglyceride structure would have little effect on lipid digestion, absorption, and metabolism in 72 
adults (10–12). However, limited research suggests that manipulating the natural position of 73 
specific FAs on the glycerol backbone may negatively affect lipoprotein metabolism, glycemic 74 
control, immune function, and serum liver enzymes (1, 13–16).  75 
The North American Branch of the International Life Sciences Institute’s Technical Committee 76 
on Dietary Lipids sponsored a workshop in Washington, DC, in 2012, to review concerns about 77 
the effects of interesterified fats on health. This workshop convened representatives from 78 
industry, government, professional associations, and academia to better understand the potential 79 
acute and chronic health effects of interesterified fats, identify research needs, and outline 80 
considerations for the design of future studies. This review summarizes the workshop findings 81 
and recommendations. 82 
CURRENT STATUS OF KNOWLEDGE 83 
Food science of interesterified fats 84 
Chemical esterification and enzymatic esterification are essential for modifying the physical 85 
properties of oils and fats and are utilized extensively in the synthesis of TGs for use as 86 
shortenings for baked goods, human milk-fat substitutes, omega-3 FA-enriched TGs, modified 87 
digestibility fats, and confectionery fat substitutes. For several decades, interesterified fats have 88 
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been added in limited amounts as hard stock for products such as margarine. The 89 
interesterification reaction can be chemical or enzymatic and is usually carried out between a 90 
high-melting-point fat (fully hydrogenated vegetable oil or palm oil fraction) and a liquid oil, 91 
leading to a FA exchange within and between TGs and resulting in the formation of new TG 92 
molecules with unique properties (desirable plasticity, texture, and mouthfeel). Chemical 93 
interesterification is a random reaction, whereas enzymatic interesterification can be specific or 94 
random, depending on the selected lipase enzymes. Sodium methoxide is generally used as a 95 
catalyst in chemical interesterification. Some commercially available lipase sources used for 96 
food processing include Candidancylindracea, Rhizomucor miehei, Mucor miehei, and 97 
Penicilliun roquefortii. The newly formed TG molecules have chemical and physical properties 98 
that fall between those of the initial starting materials. Because interesterification does not 99 
change the FA composition of the oil, the changes can only be analytically detected by a TG 100 
structural analysis.  101 
Chemical interesterification has been used since the 1940s to modify the crystallization behavior 102 
of lard. This process has disadvantages, such as high oil losses and low oxidative stability of the 103 
finished product (17). Enzymatic interesterification is preferable to chemical interesterification 104 
because it does not require chemical catalysts, can be carried out at relatively low temperatures, 105 
results in less neutral oil loss and industrial effluent, and preserves the oxidative quality of the 106 
interesterified oil. However, enzymatic interesterification also has disadvantages such as higher 107 
equipment, operating, and catalyst costs (lipase compared with sodium methoxide in chemical 108 
esterification).. Nonetheless, enzymatic interesterification has replaced chemical 109 
interesterification as the method of choice in North America, especially for formulation of low-110 
TFA or TFA-free margarines and shortenings (18).  111 
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Estimates of interesterified fats in the diet 112 
The level of intake of interesterified fats in the US population is unclear due to a lack of data on 113 
the content of interesterified fats in individual foods. Accurately estimating intake would require 114 
input from food companies or extensive analytical work, neither of which is currently available. 115 
However, changes in FA intake reported in national food intake surveys can provide some 116 
insight into intake of interesterified fats. As SFAs are incorporated into interesterified fats, 117 
intakes of palmitic and stearic acids would likely increase. In support of this, data from 2001–118 
2008 NHANES What We Eat in America suggest a shift in FA intake, including a slight increase 119 
in both palmitic and stearic acids (19–22), whereas data from 2003–2006 indicate a decrease in 120 
TFA intake (23). 121 
A modeling exercise was performed to predict FA intake subsequent to the replacement of TFA-122 
containing oils in frying processes, with oils containing fewer PUFAs (e.g., low-linolenic, mid-123 
oleic, and low-linolenic soybean oil), and replacement of TFA-containing oils in foods such as 124 
baked goods, popcorn, shortening, and stick and tub margarines (with palm-based oils or an 125 
interesterified fat made with fully hydrogenated soybean oil) (24, 25). This exercise identified 25 126 
food categories, representing 86% of total soybean oil intake and 79% of total TFA intake from 127 
NHANES 1999–2002 intake data. Twelve food categories were identified as those for which 128 
TFA-containing oils would most likely be replaced with palm oil (some of which may be 129 
interesterified) and an interesterified fat made with fully hydrogenated soybean oil. TFA intake 130 
from these 12 categories comprised approximately 50% of total TFA intake, with cakes, cookies, 131 
and other baked goods being the predominant dietary source of TFAs in the American diet (Fig. 132 
1). Based on the replacement of palm-based oils or an interesterified fat made with fully 133 
hydrogenated soybean oils in these 12 food categories (25), the predicted mean increases in the 134 
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intake of palmitic and stearic acids ranged from 1.0% to 2.0% and 0.5% to 1.5% of energy, 135 
respectively, for the mean intake of the third quintile, and 1.9% to 4.8% of energy and 0.9% to 136 
3.8% of energy, respectively, for the mean intake of the fifth quintile. The amount of total 137 
palmitic and stearic acid that currently comes from interesterified fats is unknown. However, 138 
according to the modeling exercise, if all palm oil–based products were interesterified with 139 
palmitic or stearic acid, the upper limit (the mean of the fifth quintile) of interesterified FA 140 
intake would be 4.8% of energy with a mean intake of approximately 3.0% of energy. 141 
In many of the intervention studies investigating the metabolic effect of interesterified fats as 142 
will be discussed in the next paragraphs, the interesterified fat content was well above current 143 
intakes. Based on the modeling exercise, the amount of interesterified fat (primarily containing 144 
stearic or palmitic acids) in clinical studies thus appears to be at least almost twice the amount of 145 
interesterified fat that would be consumed at the mean of the fifth quintile of intake. This raises 146 
the questions of whether the observed effects in studies are clinically relevant for most of the US 147 
population, and whether there are enough data on the effects of interesterified fats at projected 148 
typical intakes.  149 
If the goal of intervention trials is to cover the average intake levels of the population, then the 150 
third quintile of intake is a reasonable target. However, if the goal is to represent an intake that 151 
will cover most of the population, then the fifth quintile might be a better level of intervention. 152 
Both levels are significantly less than the amounts used in most intervention studies, some of 153 
which suggest that higher intakes can be problematic. It was previously suggested that the 154 
interesterified test fat must provide at least 50% of the total fat in the typical diet with 20%–40% 155 
total energy from fat to detect any possible adverse effects (14). Although understanding the 156 
effects at higher-than-usual intake levels has value, one must ensure that the data are not 157 
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misleading, particularly if such levels are not feasible in the food supply. Trials are needed in 158 
which interesterified fats are fed at intervals from 0% to 9% to elucidate their effects at predicted 159 
typical mean intakes as well as at twice the fifth quintile mean intakes. Such studies would 160 
realistically address safety concerns and would help determine whether a threshold exists above 161 
which adverse effects could occur.  162 
Digestion, absorption, and postprandial metabolism of interesterified fats  163 
The available data indicate that in healthy subjects there is minimal difference in 24-h FA 164 
absorption between TG mixtures and interesterified fats of the same composition. While 165 
preferences of the different lipases for FA chain length and saturation can be identified in vitro, 166 
the complex system in vivo is difficult to mimic and the overabundance of lipase activity masks 167 
these preferences. The exceptions may be saturated long-chain fatty acids (LCFAs) (16:0, 18:0), 168 
which may form FA-calcium soaps and are excreted to a greater degree when in the sn-1(3) 169 
position but are better absorbed from the sn-2 position because the monoglyceride is efficiently 170 
taken up by enterocytes (26). This has been clearly seen in animal studies, although human data 171 
are equivocal (12).  172 
A number of animal studies have compared the digestion and absorption of FAs from physical 173 
blends of MCFAs and LCFAs vs. interesterified TGs derived from the same mixture. Although 174 
TG lipolysis and the amount of FAs absorbed are not measurably different between TG mixtures 175 
vs. interesterified fats (except as the modifications affect solubility in mixed micelles), several 176 
investigations have shown differing rates of absorption and different lymphatic transport of FAs 177 
from interesterified lipids compared with an equivalent mixture of native oils. The position of 178 
specific FAs on the glycerol backbone seems to affect the rate of appearance and the route of 179 
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absorption in these studies. For example, MCFAs are normally transported primarily via the 180 
portal circulation; however, when they are primarily present in the sn-2 position by 181 
interesterification, a greater proportion is transported as lymph chylomicrons because they are 182 
absorbed as monoacylglycerol, which is re-esterified to TGs by enterocytes. In animal studies, 183 
both LCFAs and MCFAs are more rapidly transported into lymph from the sn-2 position than the 184 
sn-1(3) position (27–29). As a result, interesterified fats may provide a tool to increase 185 
absorption of specific FAs in clinical conditions such as malabsorption (30). In addition, greater 186 
lymphatic transport of MCFAs in interesterified fats results in better delivery to peripheral 187 
tissues of this readily utilized, high energy source, which otherwise is predominately transported 188 
to the liver through portal circulation. This is supported by both animal models (31) and clinical 189 
studies (32) that suggest interesterified fats are useful for delivering MCFAs to peripheral tissues 190 
for energy utilization. However, there is a lack of thorough, direct analysis of the acute 191 
postprandial tissue fate of lipids from interesterified compared with unmodified TGs. For 192 
example, there is little information regarding the effects of structured lipids on chylomicron size 193 
or lipoprotein composition. 194 
By using interesterified fat, it is possible to improve FA absorption in the lymph of rats 195 
following ischemia and reperfusion injury (29). Absorption of fat-soluble vitamins (33) in rat 196 
models of malabsorption and bioavailability of lipophilic drugs (34) in dog models have been 197 
shown to be enhanced by delivery with certain interesterified fats. Data are mixed regarding 198 
targeting of specific FAs with interesterified fats vs. mixtures. Together, these studies suggest 199 
that in patients with high physical stress, such as burns or surgical trauma, interesterified fats 200 
could be beneficial by diminishing nitrogen wasting and organ damage (31, 32). 201 
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Incorporation of DHA and EPA into brain phospholipids of rat dams or pups was not affected by 202 
the dietary lipid structure (35). However, EPA (but not DHA) delivery to splenocytes increased 203 
when it replaced all 18:3 FAs in the sn-2 position of TGs (36). Studies of mixed vs. 204 
interesterified TGs used in parenteral feeding to dogs revealed no differences in the FA 205 
composition of tissue fat (37).  206 
Postprandial effects of interesterified fats  207 
Whereas many clinical studies have measured the effects of dietary fats in the fasting state, 208 
humans spend most waking hours in the postprandial state. In fact, increased fasting lipoprotein 209 
and glucose concentrations as well as disturbed postprandial TG and glucose metabolism are all 210 
important risk markers for metabolic diseases (38). The postprandial period, when TGs are most 211 
elevated (3–6 h), also influences the risk of thrombosis and is considered to be a period of high 212 
risk for metabolic disease and cardiovascular events (36, 39–41). Elevated coagulation activation 213 
factors, such as factor VII (FVII), in the postprandial period may temporarily increase the risk of 214 
severe thrombotic events (42).  215 
Although postprandial data raise interesting questions related to health outcomes, they are best 216 
considered within the context of more conventional fasting data after a period of fat intervention, 217 
when a new steady-state situation is reached. Dietary fat impacts tissue phospholipid 218 
composition, particularly muscle membranes, which can affect insulin sensitivity and glucose 219 
uptake, or cell signals affecting insulin secretion (43–45). Therefore, changes in blood glucose 220 
and insulin levels should theoretically reflect the effect of interesterified fats with sn-2-SFAs 221 
such as those incorporated into phospholipids. The importance of the sn-position of a FA is 222 
further underlined by a recent trial of Kew et al. (36). Although it was not a postprandial study, 223 
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their results showed that dietary EPA increased the phagocytic capacity of activated monocytes 224 
and neutrophils when supplied in the sn-2 position, but not in the sn-1(3) position, possibly as a 225 
result of changes to membrane phospholipids of splenocytes. 226 
TG structure and FA composition may be important in affecting the FA destination in the 227 
postprandial period. There are a limited number of studies directly comparing postprandial 228 
effects of interesterified fats with native fats having identical FA composition. Of the existing 229 
studies, almost one-half included a small number of subjects (≤16) and subjects in the smaller 230 
studies were mostly healthy, young, and predominately women. However, postprandial studies 231 
are fraught with design problems such as sex selection, the amount and kind of test fat 232 
incorporated into a meal, the total nutrient composition of the test meal, the length of time the 233 
postabsorptive process is followed, and the use of subjects who have not acclimated to the fat 234 
being tested. Because each of these factors can affect the postprandial response parameters, it is 235 
imperative that design standards be established to more accurately observe the effect of a single 236 
fat in a single meal. The lack of a standardized test meal protocol among some studies makes 237 
direct comparisons difficult. However, studies conducted by Berry et al. (12, 49) and Sanders et 238 
al. (46–48) consistently used the same protocol and 50 g of test fat. 239 
Postprandial inflammation 240 
Interest in the postprandial inflammatory response has greatly increased in recent years because 241 
of its association with diabetes and metabolic disease. Postprandial findings are consistent with 242 
the theory that inflammatory responses are exacerbated by meals rich in fat. Decreasing this 243 
acute effect in the postprandial plasma compartment may protect against chronic inflammation of 244 
adipose and other tissues, which can predispose patients to insulin resistance and diabetes. 245 
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Results of several in vitro and animal studies suggest that dietary FA composition and 246 
availability can modulate inflammatory responsiveness (39, 40, 50). The differing availability of 247 
saturated LCFAs from interesterified fats vs. unmodified TGs has the potential to change 248 
postprandial inflammation, because palmitate and stearate are known to induce various 249 
inflammatory responses in vitro (40).  250 
An in vitro experiment with fasting whole blood from healthy individuals fed specific fat blends 251 
showed that the addition of unmodified LCFAs plus an MCFA-TG blend (i.e., soybean plus 252 
coconut oil) greatly increased activation and degranulation of monocytes and neutrophils, 253 
compared with the addition of interesterified TGs of similar FA composition (39). The in vivo 254 
relevance for humans is not currently known. Leukocyte activation markers were reduced in vivo 255 
when rats received parenteral MCFAs as structured TGs vs. unmodified TGs after gastrectomy 256 
surgery (50). However, monocyte chemotactic protein-1 and macrophage inflammatory protein-2 257 
levels in peritoneal lavage fluid were elevated by consumption of the structured TG, leaving the 258 
relative risk or benefit open to discussion. In addition to MCFA effects, the differing availability 259 
of saturated LCFAs from interesterified fats vs. unmodified TGs also has the potential to change 260 
postprandial inflammation, because palmitate and stearate are known to induce various 261 
inflammatory responses in vitro (40).  262 
Postprandial lipemia and factor VII  263 
In a randomized crossover study of 11 healthy men and 5 healthy women, the postprandial 264 
effects of five high-fat meals (90 g) enriched with MCFAs, such as MCTs (8:0 + 10:0), or fats 265 
rich in palmitate (16:0), stearate (18:0), elaidate (18:1 trans), and oleate (18:1 cis) were 266 
compared with a low-fat meal (51). A slower increase in postprandial plasma TGs and a lower 267 
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area under the curve were found for stearate and MCTs compared with oleate, elaidate, and 268 
palmitate-rich fats (Fig. 2).  The increase in FVIIa at 7 h was greater after the oleate meal than 269 
after the stearate and MCT meals. The authors concluded that dietary stearate-rich and MCT fats 270 
were not responsible for the postprandial increases in FVII associated with the high-fat meals. 271 
In another study of 16 healthy men, the effects of six matching high-fat meals (1 g fat/kg body 272 
wt; 43% from the test FA) were examined following breakfast on 6 separate days (42). The fats 273 
were interesterified and were rich in stearic, palmitic, palmitic + myristic, oleic, trans-18:1, or 274 
linoleic acid, and their effects on the postprandial lipid and hemostatic profiles were investigated. 275 
Although all fats increased FVII activation, there was less increase with SFAs, especially the 276 
stearic acid–rich fat (randomly interesterified hydrogenated sunflower oil blended with 277 
unhydrogenated high-oleic sunflower oil) that corresponded with its reduced postprandial 278 
triglyceridemia in comparison with UFAs.  279 
Because interesterification alters the composition of TGs and the position of the FA on the 280 
glycerol backbone, this can affect postprandial lipemia. In a randomized crossover study of 35 281 
healthy middle-aged men (n=17) and women (n=18), Sanders et al. (46) compared a structured 282 
TG (SALATRIM, a synthetic stearic acid–rich TG interesterified with short-chain FA; Danisco 283 
Cultor, Ardsley, NY) with high-oleic sunflower oil and cocoa butter after a single meal. 284 
Markedly depressed postprandial triglyceridemia occurred with SALATRIM, which is known to 285 
be absorbed more slowly (13). The depressed postprandial lipemia was accompanied by 286 
decreased activation of FVII as measured by its coagulant activity or activated concentration. 287 
There were no effects on indices of fibrinolysis (plasminogen activator inhibitor type 1 or tissue 288 
plasminogen activator). The authors proposed that this was a consequence of SALATRIM’s FA 289 
combination and randomness of the FA positional distribution, resulting in a unique asymmetric 290 
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TG structure (stearic acid combined with short-chain FAs). Some of the differences, however, 291 
may have been due to the high proportion of short-chain FAs. 292 
In a randomized crossover study of 17 healthy men, the interesterification of cocoa butter 293 
decreased postprandial lipemia and FVII activation compared with native cocoa butter (47). 294 
Berry et al. (12) compared native and interesterified shea butter (high sn-1 3-stearic acid content) 295 
and found that both native and interesterified shea butter resulted in less postprandial lipemia and 296 
decreased FVII activation compared with high-oleic sunflower oil.  297 
Sanders et al. (48) compared test meals containing 50 g of interesterified palm olein (liquid palm 298 
oil–enriched sn-2 [16:0] by interesterification) vs. an equal amount of native palm olein (sn-2 299 
[18:1, 18:2]) and 50 g of lard (sn-2 [16:0]), with an equal amount of high-oleic sunflower oil, in 300 
a two-center study in healthy men (n=25) and women (n=25). The authors hypothesized that 301 
high-fat meals rich in palmitic acid (16:0) in the sn-2 position would decrease lipemia. Sanders et 302 
al. (48) found a tendency for the initial postprandial increase in plasma TGs to be lower 303 
following consumption of the interesterified fat. Based on changes in postprandial apolipoprotein 304 
B-48 concentrations, there was no evidence indicating increased production of apolipoprotein B-305 
48 or increased resistance to chylomicron remnant clearance following the interesterified fat. 306 
There were, however, sex differences in response to the test meals for plasma TGs. For example, 307 
the postprandial incremental area under the curve (iAUC) for TGs was 51% lower in women.  308 
Postprandial glycemic control 309 
Assessing postprandial glycemic responses requires consideration of several parameters. For 310 
example, the influence of any dietary fat on glucose and insulin metabolism under experimental 311 
conditions may be influenced by study subject characteristics such as age, health status, and 312 
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genotype as well as the percentage of daily fat consumed, study length, and prior diet (52). As 313 
mentioned above, the interesterified test fat must provide at least 50% of the total fat in the 314 
typical diet with 20%–40% energy from fat in order to detect any adverse effects, because when 315 
only modestly challenged with lower levels of test fat, the body is able to compensate from UFA 316 
in adipose reserves over the short term (14).  317 
Sundram et al. (1) studied 30 healthy men and women who were fed complete, whole-food diets 318 
during 4-wk periods in a crossover design in which total fat (approximately 31% daily energy, 319 
>70% from the test fats) and FA compositions were controlled (Fig. 3). One test fat, based on 320 
palm olein, provided 12% of energy as palmitic acid (16:0). A second test fat contained trans-321 
rich partially hydrogenated soybean oil and provided 3.2% TFA, plus 6.5% energy as 16:0. The 322 
third test fat used an interesterified fat and provided 12.5% of energy as stearic acid. After 2 wk 323 
into each feeding period, an 8-h postprandial challenge was initiated in a subset of 19 subjects 324 
consuming a meal containing 53 g of each test fat. The glucose iAUC following the 325 
interesterified meal was 40% greater than after either of the other meals. However, it could also 326 
be that slower absorption of interesterified fat postprandially lowered incretin (glucagon-like 327 
peptide [GLP], GLP-1) production, leaving carbohydrates as the primary energy absorbed 328 
following the meal challenge and thus resulting in the observed glycemia. Future research is 329 
needed to explore both of these possibilities. In addition, unfavorable effects of stearic acid on 330 
postprandial glucose metabolism have not been confirmed by others (12). Furthermore, a later 331 
comparison of interesterified palm olein with native palm olein in 42 Malaysian men (n=10) and 332 
women (n=32) showed no difference in insulin secretion or postprandial glucose changes with 333 
chronic feeding (6 wk each treatment phase) at two-thirds of the dietary fat intake (53). 334 
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In two randomized crossover postprandial trials in 20 healthy men, Berry et al. (49) compared 335 
the effects of meals containing 50 g of fat as either interesterified super palm olein (sn-2–16:0, 336 
38%; 18:1, 45%; and 18:2, 11%) or native super palm olein (double fractionated liquid palm oil 337 
with sn-2–16:0, 7%; 18:1, 17%; and 18:2, 19%) (study 1) and interesterified palm oil or high-338 
oleic sunflower oil (study 2) on postprandial glucose and insulin levels. Although there was a 339 
tendency for postprandial plasma insulin to be lower and glucose to be higher with interesterified 340 
fats, the authors concluded that interesterified C16 fats did not differ significantly from naturally 341 
occurring C16 fats with regard to postprandial effects on glucose homeostasis. 342 
Sanders et al. found no differences in postprandial glucose or insulin when they compared 343 
interesterified palm olein, native palm olein, lard, and high-oleic sunflower oils, although the 344 
authors observed significant sex differences (54). As seen with TGs, there were substantial sex 345 
differences in response. The increases in plasma insulin and C-peptide were greater and those of 346 
glucose were lower in women compared with men. However, plasma glucose–dependent 347 
insulinotropic polypeptide was significantly lower following the interesterified palm olein and 348 
lard meals compared with the native palm olein and high-oleic sunflower meals; there were no 349 
differences in response between genders. The postprandial response to glucose in women was 350 
relatively flat, suggesting faster removal of glucose from plasma, with an iAUC that was 51% 351 
lower than that observed in men. Interesterified C16 fats did not differ from naturally occurring 352 
C16 fats with regard to postprandial effects on glucose homeostasis (Fig. 4).  353 
It is known that dietary lipid structure influences gut hormone release. MCTs, for example, 354 
suppress cholecystokinin release (55). However, there are no reports of how structured lipids 355 
might affect secretion of gut hormones that play important roles in insulin sensitivity and 356 
metabolic diseases (e.g., glucagon, insulin, GLP-1).  357 
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Longer-term effects of interesterified fats on fasting parameters 358 
Fasting serum lipids and lipoproteins 359 
Several studies have been carried out to examine the longer-term (i.e., 18-42 d) metabolic effects 360 
of interesterified fats. With a few noteworthy exceptions (14), most data suggest only limited 361 
differences in the longer-term effects of saturated LCFA from native TG vs. interesterified fats 362 
on fasting serum lipids and lipoproteins (56, 57). After a 3-wk intervention period, Zock et al. 363 
(57) found no major differences between the effects of palm oil and enzymatically interesterified 364 
palm oil (Betapol) on serum lipid and lipoprotein concentrations in a group of 60 healthy men 365 
(n=23) and women (n=37). Men showed a slight elevation in serum total cholesterol and LDL 366 
cholesterol with interesterified palm oil (sn-2) when they consumed diets enriched with either fat 367 
(28% of total energy; 38% energy from all fats) for 3 wk in a crossover design. However, in a 368 
study in which 20% energy from fat was exchanged, Filippou et al. (53) found no differences 369 
between native palm olein and interesterified palm olein but found that LDL cholesterol was 370 
10% higher on both interesterified and native palm olein compared to high-oleic sunflower oil 371 
when fed to 42 Malaysian men (n=10) and women (n=42) for 6 wk using a crossover design. 372 
Nestel et al. (58) drew a similar conclusion from a double-blind crossover trial of 27 373 
hypercholesterolemic men consuming three margarines for 3-wk periods: (1) a high-linoleic acid, 374 
moderate TFA margarine; (2) a high-palm oil blend (predominantly lauric, myristic, palmitic, 375 
oleic, and linoleic acids, including fully hydrogenated palm kernel oil as hard stock); and (3) an 376 
interesterified form of the high-palm oil. Each diet was fed for 3 wk using a crossover design. 377 
The study by Nestel et al. (58) in 27 hypercholesterolemic men showed that interesterification 378 
did not raise plasma cholesterol more than the high-palm oil margarine’s constituent FA, but the 379 
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latter control fat was a novel stick margarine that contained as much sn-2–SFA as its 380 
interesterified version. Christophe et al. (59) also reported no effects on the serum lipoprotein 381 
profile in a 4-wk parallel study among 32 healthy men when the consumption of butter was 382 
compared with an enzymatically interesterified butter. This might be expected because the sn-2–383 
SFA content of butterfat is so high that interesterification would not alter the sn-2–FA 384 
appreciably. On the basis of these studies, it was suggested that interesterification of 16:0-rich 385 
fats and oils does not adversely change fasting serum lipoprotein concentrations. However, 386 
evidence to the contrary exists from a trial in infants in which breast milk was compared with 387 
two formula fats (60): palm oil (sn-1,3–16:0) and enzymatic interesterified palm oil (Betapol; sn-388 
2–16:0). The enzymatic interesterified palm oil resulted in an unbeneficial increased LDL 389 
cholesterol/HDL cholesterol ratio compared with palm oil, with unaltered total cholesterol. 390 
However, the increase observed with the interesterified formula was not as great as that seen 391 
with human milk. A similar significant, but less pronounced, shift in the LDL cholesterol/HDL 392 
cholesterol ratio was noted after the exchange in sn-2–18:1 from HOSO+ canola oil in trans-18:1 393 
(partially hydrogenated vegetable oil) or interesterified-18:0 in 50 adult men in a carefully 394 
conducted crossover study with feeding periods of 6 wk (61).  395 
Grande et al. (11) found in 32 middle-aged men that natural cocoa butter (rich in stearic acid) 396 
and imitation cocoa butter (interesterified fat with the FA composition of cocoa butter) when fed 397 
for 18 d had similar effects on serum total cholesterol. Effects on LDL cholesterol and HDL 398 
cholesterol were not reported at that time. Berry et al. (12) showed in 16 men comparable effects 399 
of stearic acid–rich native and interesterified shea butter on plasma total cholesterol and TG 400 
concentrations, but the test fats represented only one-third of the daily fat. In a 3-wk study with 401 
30 men and 30 women with relatively low intake of test fats, Meijer and Westrate (10) found no 402 
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evidence that interesterification of a margarine fat blend (36% coconut oil, 33% palm oil, 22% 403 
dry-fractionated palm oil-stearin, and 9% low-trans partially hydrogenated rapeseed oil) changed 404 
serum lipid concentrations when either was then blended as a 42:58 ratio with soybean oil, 405 
rendering the availability of sn-2 (18:2) extremely high for both margarines. Sundram et al. (1), 406 
like Nelson and Innis (60) with interesterified 16:0 and Judd et al. (62) with interesterified 18:0, 407 
found that a stearic acid–rich interesterified fat (12% of energy) increased LDL cholesterol, 408 
further suggesting that 18:0 may not be neutral when randomized to sn-2 or when it becomes a 409 
major SFA in the diet. Many of these details on interesterified fat and lipoproteins were 410 
previously reviewed by Hayes and Pronczuk (14).  411 
Fasting inflammatory and hemostatic markers 412 
Most research on the effects of consuming interesterified fats has focused on postprandial lipids 413 
and glucose metabolism and, to a lesser extent, on the chronic effects of interesterification on 414 
lipoprotein profiles. Few studies have reported effects on markers of hemostasis and coagulation, 415 
either postprandially or over the long term. To date, no studies have reported the effects of 416 
interesterified fat intake on fasting inflammatory markers. 417 
Kelly et al. (63) conducted a randomized crossover study with 13 men to determine the effects of 418 
diets enriched in either palmitic acid or stearic acid on hemostatic markers. The stearic acid test 419 
fats used to alter FA composition of the diet were prepared by interesterification of 100% 420 
hydrogenated canola oil and high-oleic sunflower oil, whereas the palmitic acid test fat was 421 
prepared by interesterification of palm stearin, palm olein, and high-oleic sunflower oil. Diets 422 
were fed over 4 wk (30% of energy from fat; approximately 6.6% of energy as stearic acid in the 423 
stearic acid diet and approximately 7.8% of energy as palmitic acid in the palmitic acid diet). 424 
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Fibrinogen, plasminogen, antithrombin III, and activated partial thromboplastin time were not 425 
altered by diet. FVII (percent activity) decreased between baseline and the final day of the 426 
interesterified stearic acid diet, whereas it was not altered by the palmitic acid interesterified test 427 
diet. There were no differences in factor VIII between the two interesterified treatments at the 428 
end of the test period.  429 
Meijer and Westrate (10) conducted a double-blind crossover study with 30 men and 30 women 430 
to determine the effects of random chemical interesterification on blood lipids, enzymes, and 431 
hemostasis parameters. A blend of commonly used edible vegetable fats was compared with the 432 
same fat blend after random chemical interesterification. Both fat blends were supplied at 433 
relatively low energy levels (4% and 8%). At either energy level, the two fat blends were 434 
consumed for 3-wk periods, without an intermediate washout period. Of the 30 parameters 435 
studied, no statistically significant differences between the two fat blends were found. 436 
Fasting  glycemic control 437 
Some evidence is available on the effects of interesterified fats on glycemic control. An 438 
Australian case cohort study of 3700 women (64) assessed serum phospholipid FAs and dietary 439 
fat in relationship to type 2 diabetes mellitus and found a 4-fold increase in diabetes risk for 440 
women with the highest 18:0 in their serum phospholipids, whereas the highest quintile for 441 
phospholipid 18:2 reduced the risk to approximately 20% of the amount of the lowest quintile of 442 
18:2. Although interesterified fat consumption was not available, most interesterified fats are 443 
interesterified with 18:0 FAs, which might alter the sn-2–FAs in phospholipids to favor stearic 444 
acid. In the above-described study by Sundram et al. (1), investigators found that fasting 4-wk 445 
insulin was 22% lower after consumption of the interesterified fat compared with the palm olein.  446 
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CONCLUSIONS AND FUTURE DIRECTIONS 447 
Interesterified fats have largely replaced PHOs in processed foods, and interest in and research 448 
on their longer-term effects on health continues to grow. The consensus among workshop 449 
participants was that interesterified fat production is a feasible and economically viable solution 450 
for replacing dietary TFAs. Functionality (melting point, oxidation stability mechanical strength, 451 
laminating ability, and shortening ability) is the limiting criterion for developing healthful 452 
interesterified fats that are commercially viable. However, a fat that performs well in food 453 
applications serves no practical purpose if it cannot readily be incorporated into affordable 454 
processed foods or if consumers will not accept it. This review summarizes the current available 455 
knowledge on many important issues related to interesterified fats, including the food science of 456 
interesterified fats, estimation of interesterified fats in the diet, lipid and glucose metabolism, 457 
inflammatory and postprandial responses, longer-term effects on fasting parameters, and 458 
inflammatory and hemostatic markers. 459 
Although the above-described studies conducted on interesterified fats have not revealed any 460 
health issues, gaps in knowledge exist regarding the metabolic fate and potential health effects of 461 
longer-term consumption of interesterified fats. Outstanding questions must be answered 462 
regarding the effects of interesterification on modifying certain aspects of lipid and glucose 463 
metabolism, inflammatory responses, hemostatic parameters, and satiety. The workshop panel of 464 
experts concluded that the following areas warrant further investigation:  465 
• Effects of structured lipids on chylomicron size or apolipoprotein composition, and 466 
metabolism. 467 
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• The fate of lipids from interesterified vs. physical blends of oils in mixed TGs, 468 
including the ability of sn-2–SFAs to incorporate in fasting HDL phospholipids and 469 
their impact on HDL-phospholipid structure and function.  470 
• Effects of mixed vs. interesterified lipids on postprandial inflammatory markers in the 471 
intestine, plasma leukocytes, vascular endothelium, and adipose tissues, in light of 472 
their various roles in metabolic diseases. 473 
• Fate of LCFAs from native vs. interesterified TG presentations by methods to 474 
determine whether there are acute postprandial differences in tissues, fate, and/or 475 
metabolism that have not been apparent until now. 476 
• Whether interesterified lipids may have local effects influencing inflammation. 477 
• Effects of interesterified MCFA/intermediate chain FAs (e.g., C12–C14). 478 
• Direct comparisons of stearic-rich vs. palmitic-rich interesterified fats, with careful 479 
attention to absolute and relative abundance of the sn-2–FA, particularly 16:0, 18:0, 480 
18:1, and 18:2 over a range of percentage energy intakes. 481 
• Differential effects of interesterified fats between normal weight, overweight, and 482 
obese subjects. 483 
• Influence of higher-melting-point fats produced by interesterification on the secretion 484 
of gut peptides involved in hormonal signaling in the postprandial period that play 485 
roles in insulin sensitivity and metabolic diseases (GLP, GLP-1). 486 
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• Examination of the rate of gastric emptying after consuming fats with a high melt 487 
point, using ultrasound analysis of stomach volume, postprandially. 488 
• Long-term effects of interesterified fats on markers of inflammation, hemostatic 489 
parameters, and satiety. 490 
In addition, because clinical studies with interesterified fats have generally been conducted using 491 
intake levels that exceed the likely actual intake, future studies should carefully consider 492 
interesterified fat load in both study design and interpretation of the results. Addressing these 493 
research gaps can shed light on the longer-term effects of interesterification on human health. 494 
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FIGURE LEGENDS 690 
 691 
FIG. 1. Potential food categories for interesterified fat applications and the contribution of these 692 
categories to total trans-fatty acid (TFA) intake. The light bars represent food categories that 693 
would likely not be replaced with a functional fat, the darker shaded bars represent food 694 
categories that would likely be replaced with a heat-stable oil, and the darkest shaded bars 695 
represent food categories that would likely be replaced with an interesterified fat. Data are from 696 
Lefevre et al. (25). 697 
FIG. 2. Postprandial changes in plasma TG concentrations after consumption of six different test 698 
meals.. Eleven healthy men and 5 healthy women were given in random order a low-fat meal or 699 
five different high-fat meals (90 g) rich in medium-chain fatty acids (MCFA), palmitate (16:0), 700 
stearate (18:0), elaidate (18:1 trans), or oleate (18:1 cis). Values are given as means ± SEMs.  701 
Data are from Sanders et al. (51). 702 
FIG. 3. Individual fasting glucose values are depicted for 30 healthy men and women at study 703 
entry and after 4 wk on diets rich in test fats of palm olein (POL), partially hydrogenated 704 
soybean oil (PHSO), and interesterified fat based on fully hydrogenated soybean oil (IE). 705 
Participants consumed complete, whole-food diets during 4-wk periods in a crossover study 706 
design. Total fat comprised approximately 31% daily energy (>70% from the test fats). 707 
Compared with entry values, increases of 3%, 9%, and 22% were seen for the diets rich in palm 708 
olein, partially hydrogenated soybean oil, and interesterified fat based on fully hydrogenated 709 
soybean oil, respectively. Reproduced with permission from reference (1). 710 
 36 
FIG. 4. Sex differences in postprandial glucose among 25 women and 25 men after high-fat 711 
meals rich in interesterified palm olein, native palm olein, lard, and high-oleic sunflower oils. 712 
Women (A) and men (B) were given in random order four different high-fat meals (50 g) rich in 713 
interesterified palm olein, palm olein, lard, or high-oleic acid sunflower oil. The postprandial 714 
response to glucose in women was relatively flat, which suggests faster removal of glucose from 715 
plasma. Values are geometric means with 95% confidence intervals. For changes from fasting 716 
for the meal × times interaction, P=0.34 for both genders combined, P=0.38 for women, and 717 
P=0.39 for men. Data are from Filippou et al. (54).718 
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